Committee for Medicinal Products for Human Use (CHMP) meeting highlights
A summary of the CHMP meeting conclusions, including medicines recommended for approval and indication extension and several safety review findings.
List view / Grid view
A summary of the CHMP meeting conclusions, including medicines recommended for approval and indication extension and several safety review findings.
The FDA has approved XARELTO® (rivaroxaban) to help prevent blood clots in acutely ill medical patients.